PMID- 33847269
OWN - NLM
STAT- MEDLINE
DCOM- 20211213
LR  - 20211214
IS  - 1308-4488 (Electronic)
IS  - 1016-5169 (Linking)
VI  - 49
IP  - 3
DP  - 2021 Apr
TI  - Hyperkalemia in chronic heart failure with renal dysfunction or diabetes 
      mellitus: Results from the TREAT HF study.
PG  - 198-205
LID - 10.5543/tkda.2021.58675 [doi]
AB  - OBJECTIVE: Chronic kidney disease (CKD) and diabetes mellitus (DM) are common 
      comorbidities in heart failure (HF). Patients with HF are at a high risk of 
      hyperkalemia, and are therefore undertreated with respect to disease-modifying 
      therapies. The Turkish Research Team-Heart Failure (TREAT HF) data were analyzed 
      for the evaluation of hyperkalemia in real-life clinical practice in HF patients 
      with CKD or DM. METHODS: The TREAT HF is a multicenter, national, observational 
      registry. In this study, potassium levels of 1028 patients with HF were analyzed. 
      Hyperkalemia is defined as blood potassium levels >5 mEq/L and evaluated based on 
      the CKD, DM, HF medications, and New York Heart Association (NYHA) classes. 
      RESULTS: Overall, 14.3% of patients (n=147) were found to have hyperkalemia. 
      Hyperkalemia was more prevalent in patients with estimated glomerular filtration 
      rate (eGFR) <60 mL/min/1.73 m2 than those with eGFR >/=60 mL/min/1.73 m2 (17.7% and 
      12%, respectively, p=0.010). Hyperkalemia was present in 10.9% (n=23) of patients 
      with stage 1, 12.6% (n=50) with stage 2, 17.0% (n=52) with stage 3, and 19.5% 
      (n=22) with stage 4-5 CKD. Hyperkalemia was higher in patients with DM (20.5% vs 
      12.3%, p=0.001). Furthermore, hyperkalemia was much higher in patients with DM 
      with eGFR <60 mL/min/1.73 m2 (25.2%). The rate of hyperkalemia increased across 
      NYHA categories (NYHA-I: 9.8%, NYHA-II: 12.8%, NYHA-III: 14.4%, and NYHA-IV: 
      23.4%, p=0.030). In patients with stage 4-5 CKD who were receiving 
      renin-angiotensin-aldosterone system (RAAS) inhibitor therapy, more patients had 
      hyperkalemia than those not receiving RAAS inhibitor therapy (23.4% and 12.5%, 
      respectively). CONCLUSION: In clinical practice, 14.3% of all patients with HF, 
      17.7% of all patients with CKD, and 20.5% of all patients with DM have 
      hyperkalemia. The risk of hyperkalemia increases with advanced stages of CKD or 
      NYHA and the risk is higher in patients receiving RAAS inhibitor therapy.
FAU - Murat, Selda
AU  - Murat S
AD  - Eskisehir Osmangazi Universitesi Tip Fakultesi, Kardiyoloji Anabilim Dali, 
      Eskisehir, Turkiye.
FAU - Kaya, Hakki
AU  - Kaya H
AD  - Onsekiz Mart Universitesi Tip Fakultesi, Kardiyoloji Anabilim Dali, Canakkale, 
      Turkiye.
FAU - Cavusoglu, Yuksel
AU  - Cavusoglu Y
AD  - Eskisehir Osmangazi Universitesi Tip Fakultesi, Kardiyoloji Anabilim Dali, 
      Eskisehir, Turkiye.
FAU - Yilmaz, Mehmet Birhan
AU  - Yilmaz MB
AD  - Dokuz Eylul Universitesi Tip Fakultesi, Kardiyoloji Anabilim Dali, Izmir, 
      Turkiye.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PL  - Turkey
TA  - Turk Kardiyol Dern Ars
JT  - Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir
JID - 9426239
RN  - 0 (Antihypertensive Agents)
RN  - RWP5GA015D (Potassium)
SB  - IM
MH  - Antihypertensive Agents/therapeutic use
MH  - Diabetes Complications/blood/epidemiology/etiology
MH  - Female
MH  - Glomerular Filtration Rate
MH  - Heart Failure/blood/*complications
MH  - Humans
MH  - Hyperkalemia/epidemiology/*etiology
MH  - Male
MH  - Middle Aged
MH  - Potassium/blood
MH  - Renal Insufficiency, Chronic/blood/*complications/physiopathology
MH  - Renin-Angiotensin System
EDAT- 2021/04/14 06:00
MHDA- 2021/12/15 06:00
CRDT- 2021/04/13 08:50
PHST- 2021/04/13 08:50 [entrez]
PHST- 2021/04/14 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
AID - 10.5543/tkda.2021.58675 [doi]
PST - ppublish
SO  - Turk Kardiyol Dern Ars. 2021 Apr;49(3):198-205. doi: 10.5543/tkda.2021.58675.